Explore (New York, N.Y.)Oct 6, 2026

Why GLP-1 therapy works better for some patients: an Ayurvedic view on metabolic differences

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 7, 2026

Abstract

Genetics may explain part of the variability in individual responses to glucagon-like peptide-1 receptor agonists (GLP-1 RAs).

Individual responses to GLP-1 RAs in treating obesity and type 2 diabetes can vary significantly.
Some patients experience substantial improvements in blood sugar levels, weight, and heart health, while others face limited benefits or adverse effects.
Ayurvedic concepts suggest that differences in digestive and metabolic characteristics could affect treatment outcomes.
The framework of Ayurveda evaluates metabolic capacity and suitability for treatment before selecting therapies.
Identifying and adjusting for these gastrointestinal and metabolic traits may enhance patient tolerance and response to GLP-1 therapy.

Simplified

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the treatment of obesity and type 2 diabetes, yet individual responses vary substantially. Some patients achieve marked improvements in glycemia, weight, and cardiometabolic risk, whereas others have limited benefit, gastrointestinal intolerance, excessive weight loss, or clinically concerning loss of lean tissue. Genetics may explain part of this heterogeneity, but Ayurveda suggests an additional question: are we applying the same metabolic intervention to patients with meaningfully different digestive, nutritional, and metabolic phenotypes? Ayurveda has long described prameha as heterogeneous and evaluates agni (digestive and metabolic capacity), ama (incompletely processed or accumulated material), srotas (pathways of transport), and suitability for langhana (reducing or lightening therapy) before selecting treatment. These concepts should not be equated literally with modern biomarkers. Rather, they provide a framework for a testable contemporary hypothesis: identifying and, where possible, modifying gastrointestinal, nutritional, and metabolic phenotypes before and during GLP-1 therapy may improve tolerability and the quality of response.

Full Text

Full text is available at the source.

View Full Text ↗

Why GLP-1 therapy works better for some patients: an Ayurvedic view on metabolic differences

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief